Since BeyondSpring Inc. (NASDAQ:BYSI) and Ionis Pharmaceuticals Inc. (NASDAQ:IONS) are part of the Biotechnology industry, they are influenced by contrast. The influences particularly affect the analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation of both companies.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ionis Pharmaceuticals Inc.||67||12.23||N/A||2.58||25.76|
Demonstrates BeyondSpring Inc. and Ionis Pharmaceuticals Inc. earnings per share, top-line revenue and valuation.
Table 2 shows us BeyondSpring Inc. and Ionis Pharmaceuticals Inc.’s return on equity, return on assets and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Ionis Pharmaceuticals Inc.||0.00%||39.3%||14.4%|
BeyondSpring Inc.’s Current Ratio is 0.4 while its Quick Ratio is 0.4. On the competitive side is, Ionis Pharmaceuticals Inc. which has a 9.4 Current Ratio and a 9.4 Quick Ratio. Ionis Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to BeyondSpring Inc.
The table given features the ratings and recommendations for BeyondSpring Inc. and Ionis Pharmaceuticals Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Ionis Pharmaceuticals Inc.||0||2||1||2.33|
Ionis Pharmaceuticals Inc. on the other hand boasts of a $68.33 consensus price target and a 4.18% potential upside.
Insider and Institutional Ownership
BeyondSpring Inc. and Ionis Pharmaceuticals Inc. has shares held by institutional investors as follows: 1.6% and 85.4%. About 77.22% of BeyondSpring Inc.’s share are held by insiders. Competitively, Ionis Pharmaceuticals Inc. has 0.2% of it’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Ionis Pharmaceuticals Inc.||-3.06%||-20.66%||9.91%||29.22%||43.49%||23.1%|
For the past year BeyondSpring Inc. has -21.65% weaker performance while Ionis Pharmaceuticals Inc. has 23.1% stronger performance.
Ionis Pharmaceuticals Inc. beats on 9 of the 9 factors BeyondSpring Inc.
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.
Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. Its drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis. The company also develops IONIS-HTTRx, an antisense drug to treat patients with Huntington's disease; IONIS-SOD1Rx, an antisense drug to treat patients with an inherited form of amyotrophic lateral sclerosis; AKCEA-ANGPTL3-LRx, a LICA drug for treating multiple lipid disorders or mixed dyslipidemias; IONIS-PKKRx, an antisense drug that treats patients with hereditary angioedema; IONIS-FXIRx, an antisense drug for the treatment of thrombosis; AKCEA-APO(a)-LRx, a LICA drug that reduces apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); and AKCEA-APOCIII-LRx, an antisense drug for cardiometabolic disease. In addition, it develops IONIS-AR-2.5Rx, an antisense drug that treats patients with prostate cancer; IONIS-STAT3-2.5Rx, a cancer drug; AKCEA-ANGPTL3-LRx, a LICA drug to treat multiple lipid disorders; IONIS-GCGRRx, an antisense drug to treat patients with type 2 diabetes; and IONIS-DGAT2Rx, an antisense drug to treat patients with liver disease. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.